Karuna Therapeutics, Inc. Stock News

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy

BOSTON--( BUSINESS WIRE )--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric

Karuna Therapeutics, Inc. transitioned a new CEO in yesterday, with the former chief now president of R&D. Questions now arise on Karuna Therapeutics' suitability as a takeover candidate.

Karuna Therapeutics Inc KRTX shares are trading lower by 11.63% to $200.56 going into the close of Tuesday's session after the company announced a CEO transition.

Karuna Therapeutics (KRTX) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales.

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy

Recent clinical successes and M&A could bring interest back to biotechnology, especially among mid-capitalization names with derisked or approved products. Restructuring, corporate activity, and COVID

The biotech sector is down this year, but these two biopharmaceutical stocks have delivered strong returns.

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy

Before jumping directly into momentum stocks worth buying now, it's important to understand what momentum trading is. As the name implies, momentum trading relies on reacting to the current movement o

JMP Securities CEO Mark Lehmann joins 'Closing Bell: Overtime' to discuss why he likes health care stocks as the place to be right now.

Karuna produced excellent data from its phase 3 trial. They have a boatload of cash.

Karuna Therapeutics, Inc. (KRTX) reported earnings 30 days ago. What's next for the stock?

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric a

Biotech stocks are scorching right now. But the best of the best have strong gains.